Satellos Bioscience Inc MSLE 深 沪
已收盘 08-14 16:00:00 美东时间
9.61
-0.210
-2.14%
华盛通- 最 高10.10
- 今 开9.78
- 成交量 3.84万股
- 最 低 9.6001
- 昨 收 9.82
- 总市值 20.02万
- 52周最高 13.3949
- 市盈率 静 --
- 换手率 0.18%
- 52周最低 5.44
- 委 比 71.74%
- 总股本 2.08万
- 历史最高 13.3949
- 量 比 1.94
- 振 幅 5.09%
- 历史最低 5.44
- 每 手 1
- 风险率 1.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate
Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 43.59 percent decrease over losses of $(0.39) per share from the same period last year.
08-14 05:04
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $18
HC Wainwright & Co. analyst Arthur He maintains Satellos Bioscience (NASDAQ:MSLE) with a Buy and raises the price target from $11 to $18.
07-09 18:20
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Satellos Bioscience Inc. announced interim six-month data from the TRAILHEAD study of SAT-3247 in adults with Duchenne muscular dystrophy (DMD). Results from four participants showed improved muscle composition, increased upper limb activity, stable strength, reduced muscle damage biomarkers, and a favorable safety profile. Key findings include a 3.7% decline in muscle fat fraction, a 34% increase in TE99C (upper limb effort), maintained handgrip...
07-08 10:30
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
Satellos Bioscience Inc. announced that the FDA has granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations to its drug candidate SAT-3247 for Duchenne muscular dystrophy (DMD). Fast Track designation aims to expedite the development and review of treatments for serious conditions. SAT-3247 is currently in Phase 2 clinical trials (BASECAMP and TRAILHEAD) with additional data expected by late 2026. The drug targets AAK1, a protein...
06-29 11:00
Satellos to Present Clinical Program Updates at ICNMD 2026
Satellos Bioscience Inc. announced that new data from its SAT-3247 clinical program will be presented at the 19th International Congress on Neuromuscular Diseases in Florence, Italy, on July 8, 2026. The presentations include a poster on six-month follow-up data from Phase 1b and Phase 2 trials, as well as a Showcase Theatre presentation on SAT-3247's potential for muscle repair in Duchenne muscular dystrophy (DMD) and other degenerative muscle d...
06-25 11:00
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
Satellos Bioscience Inc. announced the results of its 2026 Annual Meeting of Shareholders held on June 17, 2026, in Toronto. All nominated directors were elected, with a voting rate of 55.3%. The directors received high support, with most receiving over 99% approval, except Stephanie Brown (92.22%) and Iris Loew-Friedrich (83.76%). Shareholders also approved the reappointment of PricewaterhouseCoopers LLP as auditors. Satellos is developing SAT-3...
06-17 21:00
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $11 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $11 price target.
05-19 01:53
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
